Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations
- 31 December 2009
- journal article
- research article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 36, S18-S25
- https://doi.org/10.1053/j.seminoncol.2009.10.009
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein SynthesisCancer Research, 2008
- Defining the Role of mTOR in CancerCancer Cell, 2007
- Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced CancerClinical Cancer Research, 2006
- Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With CancerJournal of Clinical Oncology, 2004
- The tor pathway: a target for cancer therapyNature Reviews Cancer, 2004
- Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumorsAnnals of Oncology, 2003
- An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity inPten+/−miceProceedings of the National Academy of Sciences of the United States of America, 2001
- RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTINGThe Lancet, 1989